On Tuesday, Genmab ADR (NASDAQ: GMAB) was 0.05% up from the session before settling in for the closing price of $20.02. A 52-week range for GMAB has been $19.85 – $32.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43.21%. When this article was written, the company’s average yearly earnings per share was at 27.98%. With a float of $635.23 million, this company’s outstanding shares have now reached $635.24 million.
Let’s determine the extent of company efficiency that accounts for 2204 employees. In terms of profitability, gross margin is 96.08%, operating margin of 32.33%, and the pretax margin is 32.83%.
Genmab ADR (GMAB) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Genmab ADR stocks. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 8.28%.
Genmab ADR (GMAB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.96% during the next five years compared to 20.52% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
You can see what Genmab ADR (GMAB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.43. Likewise, its price to free cash flow for the trailing twelve months is 13.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.04, a number that is poised to hit 0.35 in the next quarter and is forecasted to reach 1.36 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
Looking closely at Genmab ADR (NASDAQ: GMAB), its last 5-days average volume was 1.12 million, which is a jump from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 5.46%. Additionally, its Average True Range was 0.45.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 2.07%, which indicates a significant decrease from 7.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.16% in the past 14 days, which was higher than the 26.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.06, while its 200-day Moving Average is $26.30. However, in the short run, Genmab ADR’s stock first resistance to watch stands at $20.24. Second resistance stands at $20.45. The third major resistance level sits at $20.62. If the price goes on to break the first support level at $19.86, it is likely to go to the next support level at $19.69. Now, if the price goes above the second support level, the third support stands at $19.48.
Genmab ADR (NASDAQ: GMAB) Key Stats
There are 661,768K outstanding shares of the company, which has a market capitalization of 12.72 billion. As of now, sales total 2,392 M while income totals 631,910 K. Its latest quarter income was 816,600 K while its last quarter net income were 186,610 K.
